| Agonist activity at human GalR2 expressed in CHO-K1 cells at 1.25 uM by calcium mobilization assay relative to Galanin (2-29) - BioAssay Summary Galanin modulates seizures in the brain through two galanin receptor subtypes, GalR1 and GalR2. To generate systemically active galanin receptor ligands that discriminate between GalR1 and GalR2, the GalR1-preferring analogue Gal-B2 (or NAX 5055) was rationally redesigned to yield GalR2-preferring analogues. Systematic truncations of the N-terminal backbone led to [N-Me,des-Sar]Gal-B2, containing more .. |
_ | |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Target
Tested Compound: Description: Title: Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. Abstract: Galanin modulates seizures in the brain through two galanin receptor subtypes, GalR1 and GalR2. To generate systemically active galanin receptor ligands that discriminate between GalR1 and GalR2, the GalR1-preferring analogue Gal-B2 (or NAX 5055) was rationally redesigned to yield GalR2-preferring analogues. Systematic truncations of the N-terminal backbone led to [N-Me,des-Sar]Gal-B2, containing N-methyltryptophan. This analogue exhibited 18-fold preference in binding toward GalR2, maintained agonist activity, and exhibited potent anticonvulsant activity in mice following intraperitoneal administration. (PMID: 20121116) Categorized Comment ChEMBL Assay Type: Functional ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 11498 ChEMBL target type: Target is a single protein chain Result Definitions
Data Table (Concise) Classification
PageFrom: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||